It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores. What ...

BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sustainability Roundtable, Inc. (SR Inc), a leader in strategic advisory and support services, proudly announces the recipients of its 2024 Sustainable Business & Enterprise Roundtable (SBER) Awards. Presented the eve before its Summit for Sustainable Business VIII: Decarbonizing Corporate Global Operations at the St. Regis hotel in Washington, D.C., these recognitions commemorate SBER's 2024 standout sustainability leaders. Award Recipients and Achievements SR Inc ...

One of my favorite ways to add money to my portfolio is to invest in proven compounders with track records of delivering market-beating results after short-term pullbacks. This idea is especially true when the stocks in question are trading at what could prove to be once-in-a-decade opportunities.Two companies that fit this description now are animal healthcare specialists Idexx Laboratories (IDXX 0.02%) and Zoetis (ZTS 0.94%). While Idexx is already one of my daughter's core holdings and Zoetis is one of ...

IDEXX Laboratories, Inc.’s (IDXX) consistent strong performance of the CAG (Companion Animal Group) segment is poised to help it grow in the upcoming quarters. Robust demand for its cloud-based offerings instills optimism, reflecting the company’s focus on improving patient care rather than back-office tasks. Solid performance in the international markets is encouraging. However, unfavorable solvency and the impact of third-party distributors remain our concerns for IDEXX’s operations. In the past year, thi ...

More than 15 years of professional investment experience in global equities across all sectors. My investment style is fundamental, bottom-up, long-term, and quality growth-oriented. I am seeking companies specializing in niche markets, with strong growth potential, a solid management team, a sound capital allocation policy, and, most importantly, reasonable valuation. I do not chase quarterly results, nor do I follow the herd mentality. I do not use short-term stock performance as the measure of a company' ...

Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today.While the debate over whether it's better to pay for high-quality or high-growth businesses will never end, the easiest solution is to find stocks offering both.One company that fits this best-of-both-worlds billing is Idexx Laboratories (IDXX 0.19%), offering leading pet healthcare diagnostics operations. Delivering annualized revenue and free-cash-flow growth of 10% and ...

FOR IMMEDIATE RELEASE Contact: John Ravis, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Third Quarter Results ▪ Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. ▪ Organic revenue growth supported by benefits from IDEXX execution drivers including continued solid new business gains and double-digit year-over-year global premium installed base growth. ▪ Delivers EPS of $2.80, an incre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. COMMISSION FILE NUMBER: 000-19271 IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter) Dela ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vasquez - William Blair David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. ...

IDEXX Laboratories, Inc. (IDXX) posted third-quarter 2024 earnings per share (EPS) of $2.80, up 10.7% year over year. The figure surpassed the Zacks Consensus Estimate by 4.1%.Comparable constant-currency EPS of $2.79 improved 12% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, IDXX stock fell 3.1% at the pre-market trading today.IDEXX’s Revenues in DetailQuarterly revenues increased 6.6% year over year (up 6% organically) to $975.5 ...